PAMELA B. STUART v. BARBARA J. WALKER

143 A.3d 761, 2016 D.C. App. LEXIS 261, 2016 WL 4061660
CourtDistrict of Columbia Court of Appeals
DecidedJuly 28, 2016
Docket14-CV-1443
StatusPublished
Cited by2 cases

This text of 143 A.3d 761 (PAMELA B. STUART v. BARBARA J. WALKER) is published on Counsel Stack Legal Research, covering District of Columbia Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
PAMELA B. STUART v. BARBARA J. WALKER, 143 A.3d 761, 2016 D.C. App. LEXIS 261, 2016 WL 4061660 (D.C. 2016).

Opinion

BLACKBURNE-RIGSBY, Associate Judge:

Pro se appellant Pamela B. Stuart, a member of the District of Columbia Bar, appeals the trial court’s granting of a motion to. compel arbitration,, pursuant to D.C. Bar R. XIII, 1 to resolve a fee dispute with her former client, pro se appellee Barbara J. Walker. 2 Ms. Stuart contends that this court lacked the authority to promulgate Rule XIII under the District of Columbia Court Reform and Criminal Procedure Act of 1970 (“Court Reform Act”), D.C.Code § ll-2501(a) (2012 Repl.), the Home Rule Act, D.C.Code § l-206.02(a)(4) (2012 Repl.), and the United States Constitution. We have already upheld Rule'XIII as valid and constitutional in BiotechPharma v. Ludwig & Robinson, PLLC, 98 A.3d 986 (D.C.2014). 3 In this post-arbitration appeal, Ms. Stuart challenges Rule XIII, and she raises essentially the same' arguments, save two, that this court addressed in BiotechPharma. After a brief review of the arguments raised and this court’s holding in BiotechPharma, we address the two new challenges Ms. Stuart raises. For the reasons discussed below, we reject Ms. Stuart’s arguments and affirm.

I. Factual Background-

Ms. Stuart represented Ms. Walker in a lawsuit against her former employer, and entered into an oral fee agreement, which did not specifically discuss arbitration of fee disputes. Ms. Walker contested the amount of fees billed and refused to pay, prompting Ms. Stuart to file a civil claim for fraud and breach of contract against Ms. Walker for unpaid legal fees and expenses (including accrued interest) in the amount of $127,928.30. In response, Ms. Walker filed a request to arbitrate the dispute with the District of Columbia Bar’s Attorney-Client Arbitration Board, pursuant to Rule XIII. Ms. Stuart objected to arbitration, but the trial court issued an order compelling the parties to arbitrate. 4

*764 The arbitration panel rendered a decision ordering Ms. Walker to pay Ms. Stuart $6,860 within 90 days and requiring each party to bear her own costs for the arbitration. Ms. Stuart filed a motion to vacate the award and set the matter for trial, arguing that Rule XIII is invalid and unconstitutional and that the $6,860 award was arbitrary and capricious. The trial court held a hearing and denied Ms. Stuart’s motion to vacate the award based on this court’s recent decision in BiotechPharma, which affirmed the validity of Rule XIII under the Court Reform Act, the Home Rule Act, and the United States Constitution. The trial court also found that Ms. Stuart’s contention that the award was arbitrary and capricious was not a cognizable basis for review. See D.C.Code § 16-4423(a) (2012 Repl.) (listing the available grounds for reviewing an arbitration award). This appeal followed.

II. Discussion

A. BiotechPharma Holding

BiotechPharma squarely addresses the majority of Ms. Stuart’s arguments concerning Rule XIII. In BiotechPharma, the appellant argued that: 1) this court lacked the express authority from Congress to promulgate Rule XIII; 2) Rule XIII violates the Home Rule Act 5 by removing attorney-client fee disputes from the jurisdiction of the District of Columbia courts, by vesting judicial authority in non-lawyer members of arbitration panels, and by limiting the scope of judicial review of arbitration awards; and 3) Rule XIII violates attorneys’ Seventh Amendment right to a jury trial and their Fifth Amendment right to due process. BiotechPharma, supra, 98 A.3d at 994-95, 998. The court rejected those arguments.

BiotechPharma held that the Court Reform Act gives this court the statutory authority to “make such rules as it deems proper” concerning the affairs of the District of Columbia Bar. D.C.Code § 11-2501(a) (2012 Repl.). The BiotechPharma court further held that as “the highest court [of] the jurisdiction,” this court possesses “the inherent authority to define, regulate, and control the practice of law in th[is] jurisdiction.” BiotechPharma, supra, 98 A.3d at 994 (quoting Sitcov v. District of Columbia Bar, 885 A.2d 289, 295, 297 (D.C.2005)). Together, “both the inherent and statutory authority” allow this court to “regulate virtually every aspect of legal practice in the District of Columbia, including the substance of fee agreements,” which is the subject matter of Rule XIII. Id.

BiotechPharma also held that Rule XIII does not run afoul of the Home Rule Act, which prohibits the Council for the District of Columbia from altering the D.C. courts’ jurisdiction, because mandatory arbitration under the rule does not modify the courts’ jurisdiction, but instead creates an implied agreement between attorneys and them clients. Id. at 994. Specifically, mutual assent to the arbitration agreement occurs when “[attorneys sub *765 mit to the role by practicing law in the District of Columbia,” and “[c]lients invoke the rule by requesting arbitration.” Id. at 994. Accordingly, any quasi-judicial authority vested in the Attorney-Client Arbitration Board “is limited to fee disputes between”- attorneys and their clients “who have voluntarily chosen to submit to the board’s determination.” 6 Id. at 995. Thus, Rule XIII does not violate the Home Rule Act because it does not alter this court’s' jurisdiction “any more than any other agreement to arbitrate would.” Id.

Finally, BiotechPharma held that Rule XIII does not viólate the Seventh Amendment right to a jury trial or the right to due process. Attorneys are deemed to waive their Seventh Amendment right to a jury trial for fee disputes under Rulé XIII “[b]ecause an arbitration agreement necessarily embodies a waiver” of that right. Id. at 996-97 (citing Kelley Drye & Warren v. Murray Indus., 623 F.Supp. 522, 527 (D.N.J.1985) and Geldermann, Inc. v. Commodity Futures Trading Comm’n, 836 F.2d 310, 318 (7th Cir.1987) to conclude that Rule XIII and similar rules do not violate an attorney’s Seventh Amendment right to a jury trial).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Illinois Farmers Insurance Co. v. Hagenberg
167 A.3d 1218 (District of Columbia Court of Appeals, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
143 A.3d 761, 2016 D.C. App. LEXIS 261, 2016 WL 4061660, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pamela-b-stuart-v-barbara-j-walker-dc-2016.